Aster DM Healthcare and Quality Care India Limited have signed definitive agreements to merge, subject to regulatory, corporate and shareholders’ approvals
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Subscribe To Our Newsletter & Stay Updated
